Drug-induced long QT syndrome and fatal arrhythmias in the intensive care unit

Acta Anaesthesiologica Scandinavica

Volumn 58, Issue 3, 2014, Pages 266-272

  Beitland, S ^a,b   Platou, E S ^b   Sunde, K ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT;

ADVERSE DRUG REACTION; ARRHYTHMIAS, CARDIAC; CHEMICALLY INDUCED; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; LONG QT SYNDROME; META ANALYSIS; PROCEDURES;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; LONG QT SYNDROME;

EID: 84894360357     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/aas.12257     Document Type: Review

References (36)

1. Zipes DP, Wellens HJJ,. Sudden cardiac death. Circulation 1998; 98: 2334-2351.
2. Myerburg RJ, Kessler KM, Castellanos A,. Sudden cardiac death: epidemiology, transient risk and intervention assessment. Ann Intern Med 1993; 119: 1187-1197.
3. Barsheshet A, Brenyo A, Moss AJ, Goldenberg I,. Genetics of sudden cardiac death. Curr Cardiol Rep 2011; 13: 364-376.
4. Abdon NJ, Herlitz J, Bergfeldt L,. Drug-induced cardiac arrest maybe more common than believed. Lakartidningen 2010; 107: 521-525.
5. Kenigsberg DN, Khanal S, Kowalski M, Krishnan SC,. Prolongation of the QTc interval is seen uniformly during early transmural ischemia. JACC 2007; 49: 1299-1305.
6. Pickham D, Flowers E, Drew BJ,. Hyperglycemia is associated with corrected QT prolongation and mortality in acutely ill patients. J Cardiovasc Nurs 2013; doi: 10.1097/JCN.0b013e31827f174c
7. Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE,. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. Scientific World Journal 2012; 212178. doi: 10.1100/2012/212178.
8. Drew BJ, Califf RM, Funk M, Kaufman ES, Krucoff MW, Laks MM, Macfarlane PW, Sommargren C, Swiryn S, Van Hare GF,. Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association Scientific Statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: endorsed by the International Society of Computerized Electrocardiology and the American Association of Critical-Care Nurses. Circulation 2004; 110: 2721-2746.
9. Armahizer MJ, Seybert AL, Smithburger PL, Kane-Gill SL,. Drug-drug interactions contributing to QT prolongation in cardiac intensive care units. J Crit Care 2013; 28: 243-249.
10. Pickham D, Helfenbein E, Shinn JA, Chan G, Funk M, Drew BJ,. How many patients need QT interval monitoring in critical care units? Preliminary report of the QT in Practice study. J Electrocardiol 2010; 43: 572-576.
11. Pickham D, Helfenbein E, Shinn JA, Chan G, Funk M, Weinacker A, Liu JN, Drew BJ,. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in Practice (QTIP) Study. Crit Care Med 2012; 40: 394-399.
12. De Bruin ML, Langendijk PN, Koopmans RP, Wilde AA, Leufkens HG, Hoes AW,. In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs. Br J Clin Pharmacol 2007; 63: 216-223.
13. Roden DM, Woosley RL, Primm RK,. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 1986; 111: 1088-1093.
14. Viskin S, Rosovski U, Sands AJ, Chen E, Kistler PM, Kalman JM, Rodriguez Chavez L, Iturralde Torres P, Cruz FFE, Centuriõn OA, Fujiki A, Maury P, Chen X, Krahn AD, Roithinger F, Zhang L, Vincent GM, Zeltser D,. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm 2005; 2: 569-574.
15. Muzyk AJ, Rayfield A, Revollo JY, Heinz H, Gagliardi JP,. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol. Drug Saf 2012; 35: 547-553.
16. Geng DF, Jin DM, Wang JF, Luo YJ, Wu W,. Clinical study of amiodarone-associated torsade de pointes in Chinese people. Pacing Clin Electrophysiol 2006; 29: 712-718.
17. Diaz-Castro O, Puchol A, Almendral J, Torrecilla EG, Arenal A, Martinez-Selles M,. Predictors of in-hospital ventricular fibrillation or torsades de pointes in patients with acute symptomatic bradycardia. J Electrocardiol 2004; 37: 55-60.
18. Lazzara R,. Amiodarone and torsade de pointes. Ann Intern Med 1989; 111: 549-551.
19. Oberg KC, Bauman JL,. QT interval prolongation and torsades de pointes due to erythromycin lactobionate. Pharmacotherapy 1995; 15: 687-692.
20. Tschida SJ, Guay DR, Straka RJ, Hoey LL, Johanning R, Vance-Bryan K,. QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature. Pharmacotherapy 1996; 16: 663-674.
21. Antzelevitch C, Sun ZQ, Zhang ZQ, Yan GX,. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 1996; 28: 1836-1848.
22. Miller JL, Ashford JW, Archer SM, Rudy AC, Wermeling DP,. Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: a pilot pharmacokinetic study. Pharmacotherapy 2008; 28: 875-882.
23. Miyaji S, Yamamoto K, Hoshino S, Yamamoto H, Sakai Y, Miyaoka H,. Comparison of the risk of adverse events between risperidone and haloperidol in delirium patients. Psychiatry Clin Neurosci 2007; 61: 275-282.
24. Sharma ND, Rosman HS, Padhi ID, Tisdale JE,. Torsades de Pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81: 238-240.
25. Tisdale JE, Rasty S, Padhi ID, Sharma ND, Rosman H,. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes. J Clin Pharmacol 2001; 41: 1310-1318.
26. Wilt JL, Minnema AM, Johnson RF, Rosenblum AM,. Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med 1993; 119: 391-394.
27. Laszlo R, Laszlo S, Kettering K, Schreieck J, Riessen R,. Drug-induced long QT syndrome. Relevancy in intensive care medicine. Med Klin Intensivmed Notfmed 2012; 107: 197-205.
28. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W,; American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology, the Council on Cardiovascular Nursing, and the American College of Cardiology Foundation. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010; 121: 1047-1060.
29. Hondeghem LM,. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. J Cardiovasc Electrophysiol 2006; 17: 337-340.
30. LaPointe NM, Al-Khatib SM, Kramer JM, Califf RM,. Knowledge deficits related to the QT interval could affect patient safety. Ann Noninvasive Electrocardiol 2003; 8: 157-160.
31. Damiano BP, Rosen MR,. Effects of pacing on triggered activity induced by early afterdepolarizations. Circulation 1984; 69: 1013-1025.
32. Freeman BD, Dixon DJ, Coopersmith CM, Zehnbauer BA, Buchman TG,. Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients. Pharmacoepidemiol Drug Saf 2008; 17: 971-981.
33. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH,. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287: 2215-2220.
34. Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ,. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med 2010; 5: E8-16.
35. Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, Sramek J, Shiovitz T, Middle M,. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004; 24: 62-69.
36. Kozik TM, Wung SF,. Acquired long QT syndrome: frequency, onset, and risk factors in intensive care patients. Crit Care Nurse 2012; 32: 32-41.